SNDK, PTGX and LION made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13th, 2026.
Zacks
More News
New Strong Buy Stocks for July 13th
FOX, LION, EDRY, PTGX and SPH have been added to the Zacks Rank #1 (Strong Buy) List on July 13th, 2026.
Zacks
New Strong Buy Stocks for July 9th
PTGX, DHX, COOK, XYZ and ARLP have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2026.
Zacks
Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?
Protagonist Therapeutics (PTGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.
Zacks
J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates may give one stock an edge.
Zacks
J&J Stock Down 3% in 3 Months: Is the Dip a Buying Opportunity?
J&J's shares fall 3% in three months despite solid results and pipeline progress, raising questions about whether the pullback is a buying opportunity.
Zacks
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.
Zacks
J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?
JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.